NCT06971913View on ClinicalTrials.gov

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
SLE (Systemic Lupus)CMV
Interventions
DRUG

Interleukin-2 (IL-2)

Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.

DRUG

Ganciclovir (GCV)

Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER